Roundview Capital LLC Has $1.54 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Roundview Capital LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 46.6% during the second quarter, HoldingsChannel reports. The fund owned 3,785 shares of the medical research company’s stock after selling 3,304 shares during the quarter. Roundview Capital LLC’s holdings in Thermo Fisher Scientific were worth $1,535,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mondrian Investment Partners LTD grew its position in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after purchasing an additional 127,357 shares in the last quarter. Caledonia Investments PLC grew its position in Thermo Fisher Scientific by 11.5% in the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after purchasing an additional 11,500 shares in the last quarter. Foresight Group Ltd Liability Partnership grew its position in Thermo Fisher Scientific by 3,242.7% in the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after purchasing an additional 56,747 shares in the last quarter. Advisors Capital Management LLC grew its position in Thermo Fisher Scientific by 6.7% in the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company’s stock worth $63,201,000 after purchasing an additional 7,967 shares in the last quarter. Finally, New England Research & Management Inc. grew its position in Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company’s stock worth $1,033,000 after purchasing an additional 567 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.8%

TMO opened at $539.54 on Wednesday. The company has a 50 day moving average of $484.90 and a 200 day moving average of $447.60. The company has a market cap of $203.73 billion, a PE ratio of 31.21, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Analyst Ratings Changes

A number of research firms have recently weighed in on TMO. Weiss Ratings reissued a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price for the company in a research report on Friday, July 11th. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating for the company. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Finally, UBS Group increased their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $591.16.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last three months. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.